CRP High Sensitivity (hsCRP)
Test Code: 4547CPT: 86141
|Tests Included||C-Reactive Protein|
|Use||High sensitivity CRP (hsCRP)
measurements, when used in conjunction with traditional clinical laboratory evaluation of acute coronary syndromes, may be useful as an
independent marker of prognosis for recurrent events, in patients with stable coronary disease or acute coronary syndromes.1,2
|Clinical Utility||Studies have also shown that the detection of much lower CRP levels can provide valuable information. The typical CRP concentration for healthy adults is (depending on the specific level of the individual patient) < 1 mg/L3 . Slightly higher values can indicate an increased risk for coronary heart disease in asymptomatic patients.1,2 CRP concentrations above 3 mg/L, at the time of hospital admission, predict a precarious outcome after a myocardial infarct.4 The following relative risk categories in relation to average CRP level have been recommended5 : Low < 1mg/L, Average 1.0 to 3.0 mg/L and High > 3.0 mg/L. Increases in C-Reactive Protein values are not specific and should not be interpreted without a complete clinical history since CRP is an acute phase protein which can rise non-specifically due to other inflammatory conditions. For cardiac risk analysis, other cardiac disease-specific testing must be done, such as Total cholesterol, HDL cholesterol, and LDL cholesterol. When being used for risk assessment, levels of CRP > 10 mg/L should be evaluated for other non-cardiovascular origins. Testing for any risk assessment should not be performed while there is indication of infection, systemic inflammation, or trauma|
|Intended Patient Population||18+ and Older Adult Males & Females|
|Patient Preparation||None Specified|
|Tube||Red, Green, Tiger|
|Volume||4mL Whole Blood (1mL Serum/Plasma)|
|Min Sample Volume||0.5 mLs|
|Reference Ranges||M & F ≥ 18 yrs old; < 3 mg/L|
|Analytical Measurement Range||0.2-80 mg/L|
|Test Turnaround Time||1 Day|
|Specimen Stability||7 Days RF|
|Reject Criteria||Gross Hemolysis|
|Laboratory Developed Test (LDT)||Yes|
|References||1. Morrow, A.D., Ridker, P.M. C-reactive protein, inflammation, and coronary risk Med. Clin. of North Am. 2000; 84: 149161.
2. Ridker, P.M. Novel risk factors and markers for coronary disease. Adv. Int. Med.2000; 45: 391-419.
3. Raifai N, Ridker PM. Population Distributions of C-reactive Protein in Aparently Healthy Men and Women in the United States: Implication for Clinical
Interpretation. Clin Chem 2003;49:666-669.
4. Ridker, P.M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., Braunwald, E., C-Reactive Protein Levels and Outcomes
after Statin Therapy. N. Eng. J. Med. 2005, 352, 20-28.
5. Pearson TA et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare
professionals from the Centers for Disease Control and Prevention and the American Heart Association. http://www.circulationaha.org.
6. NACB “Biomarkers of Acute Coronary Syndrome & Heart Failure” (draft guidelines) R.H. Christianson, et al AACC Press, 2004